Epigenetic marks on the DNA are critical in regulating gene expression, and allow cells to differentiate and respond to environmental stimuli. The importance of these epigenetic marks in inflammation and cancer is evident, and molecules have been newly developed to intervene with these marks (Nicodeme et al, Nature 2011; Kruidenier et al, Nature 2012; Ntziachristos et al, Nature 2014). Such compounds turn out to have extremely anti-inflammatory effects in macrophages, dendritic cells and monocytes, as well as in their target cells (Nicodeme et al, Nature 2010; Kruidenier et al, Nature 2012). In this project we aim to establish the repertoire of epigenetic marks in inflammatory cells, identify the epigenetic landscape in inflammatory cells of the inflamed colon mucosa and intervene with these marks to reduce inflammation in inflammatory bowel disease (IBD) and chronic inflammatory diseases. The work includes the characterization of genetically modified mouse strains in models of chronic (intestinal) inflammation. Furthermore, analyses of clinical trial material and experimental pre-clinical models will be carried out in close collaboration with the AMC IBD trial unit.

We are recruiting enthusiastic and creative PhD students to join the team that works on the impact of epigenetic processes on the course of IBD. We are looking for 1 bioinformatics student (experience in the laboratory is a preference) and 4 (bio)medical students with proven affinity with epigenetics and immunology. GCP- and/or animal experimentation certifications are considered a preference but can also be obtained during the project course.

Further details:
http://www.academictransfer.com